A Case of Neonatal Monkeypox Treated With Oral Tecovirimat

Pediatrics. 2024 Jan 1;153(1):e2023061198. doi: 10.1542/peds.2023-061198.

Abstract

Since the Monkeypox virus outbreak erupted in May 2022, infection has been reported across all ages. Few cases exist in the medical literature about Monkeypox infection in neonates, and little is known about its clinical manifestations, disease course, or side effects of available antiviral agents in this age group. In this report, we describe the case of a 10-day-old neonate from the southern United States who presented with fevers and generalized papulopustular rash. She was treated empirically as a febrile neonate but mpox infection was suspected early because of the characteristic exanthem and its similarity to her mother's rash that she had developed a few days before the patient's presentation. Oral tecovirimat was initiated on the third day of admission and mpox was later confirmed by polymerase chain reaction analysis. The patient tolerated oral tecovirimat well and experienced a favorable outcome without lasting effects of infection.

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents* / therapeutic use
  • Benzamides
  • Exanthema*
  • Female
  • Fever
  • Humans
  • Infant, Newborn
  • Mpox (monkeypox)* / drug therapy

Substances

  • Antiviral Agents
  • Benzamides
  • tecovirimat